IDH1 and cholangiocarcinoma: For instance, the use of poly(adenosine 5′-diphosphate) ribose polymerase inhibitors (PARPis) has been demonstrated to be beneficial in the treatment of IDH-mutant gliomas and cholangiocarcinomas, due to its capacity to reduce DNA damage [16,46,47].